Effective combined immunochemotherapy with dinitrochlorobenzene and fotemustine in skin and brain metastases of melanoma.
Göring
H D
HD
Zierner
A
A
Kröning
Y
Y
Trebing
D
D
Kämpgen
E
E
Bröcker
E B
EB
D000485:Allergens / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000556:secondary* / Q000628:therapy; D003131:Combined Modality Therapy; D017449:Dermatitis, Allergic Contact / Q000209:etiology / Q000276:immunology*; D004137:Dinitrochlorobenzene / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy; D007509:Irritants / Q000627:therapeutic use*; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000276:immunology / Q000556:secondary* / Q000628:therapy; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D012074:Remission Induction; D016879:Salvage Therapy; D012878:Skin Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000556:secondary* / Q000628:therapy
D000485:Allergens; D000970:Antineoplastic Agents; D004137:Dinitrochlorobenzene; D007509:Irritants; D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; C054368:fotemustine